An intriguing report documented loss of heterozygosity (LOH) at the HLA locus, with loss of HLA-C∗08:02 in the resistant lesion from a tumor treated with tumor-infiltrating lymphocytes composed of T cell clones targeting KRAS G12D (Tran et al., 2016). Here, KRAS is linked to neoplasm.